Karsinoid Sendromlu Olguda Anestezik Yaklaşım

Authors

Çağatay Küçükbingöz
Barış Arslan

Synopsis

This case report examines the anesthetic management of a 60-year-old male patient diagnosed with a small intestinal neuroendocrine tumor and subobstruction, who presented with epigastric pain, diarrhea, flushing, and weight loss over the past 6 months. In the preoperative period, the patient had elevated urinary 5-HIAA levels (45 mg 24 h⁻¹) and was started on octreotide therapy for symptom control. 12 hours prior to surgery, intravenous octreotide infusion was initiated alongside sedation and antihistamine premedication. Following rapid sequence induction with midazolam, lidocaine, propofol, fentanyl, and rocuronium, the patient was intubated and maintained with sevoflurane. During primary tumor resection, an acute hypertensive surge (systolic blood pressure reaching 205 mmHg) was successfully managed using fentanyl, octreotide, and an esmolol infusion. During hepatic metastasis resection, central venous pressure was temporarily lowered using furosemide and sodium nitroprusside. Following the successful 3-hour procedure, neuromuscular blockade was reversed with sugammadex, the patient was transferred to the intensive care unit, and postoperative analgesia was provided via patient-controlled tramadol. Octreotide therapy was tapered over 2 weeks, leading to an uneventful discharge. Successful carcinoid tumor surgery requires multidisciplinary planning, preoperative optimization, protocol-guided intraoperative crisis control, and tailored postoperative care.

References

Cyprian M, Carl H, Josephine J, GS Anil K. The structured oral examination in clinical anaesthesia; practice examination papers. 1st Edition. Harley: tfm Publishing Limited;2009.

Satya Prakash MVS. Perioperative Management of carcinoid syndorme-an anaesthesiologist’s perspective. J Anesth Clin Res. 2016:7; 663

Mancuso K, Kaye AD, Boudreaux JP, et al. Carcinoid syndrome and perioperative anesthetic considerations. J Clin Anesth. 2011; 23(4): 329-341.

Kaltsas G, Caplin M, Davies P, et al. ENETS Consensus guidelines for the standards of care in neuroendocrine tumors: pre- and perioperative therapy in patients with neuroendocrine tumors. Neuroendocrinology. 2017;105(3): 245-254.

Dierdorf SF. Carcinoid tumor and carcinoid syndrome. Curr Opin Anaesthesiol. 2003;16(3): 343-347.

Borna RM, Jahr JS, Kmiecik S, et al. Pharmacology of octreotide: clinical implications for anesthesiologists and associated risks. Anesthesiol Clin . 2017;35(2): 327-339.

Nielsen PT, Cowan PJ. Total intravenous anesthesia (TIVA) for carcinoid syndrome--a case report. Middle East J Anaesthesiol. 2008; 19(5): 949-955.

Farling PA, Durairaju AK. Remifentanil and anaesthesia for carcinoid syndrome. Br J Anaesth. 2004; 92(6); 893-895.

Rebêlo I, Mauricio S, Coelho D, Gaspar A. Anesthetic management of carcinoid syndrome: is octreotide enough? A case report. Revista mexicana de anestesiologia. 2019:42(2); 133-136.

Published

January 13, 2022

License

License